MICB and COVID-19: In the future, demonstrating MICB-driven differences in abundance and functionality of NK cells in the lung longitudinally during COVID-19, ideally starting from the onset of symptoms, would help develop interventions that can exploit this pathway in preventing the most critical outcomes.